Skip to content
Catalyst

knowcompoundsphylloquinone

Specimen compound organic compoundPlate I

Phylloquinone

Nested hairline contours trace the electron density of one computed shape of phylloquinone, teal at the edge warming to amber over the atoms.
fig. 1Phylloquinone · electron density · PubChem CID 5284607, computed 3D conformer
Formula
C31H46O2
Molar mass
450.707 g/mol
PubChem CID
5284607
InChIKey
MBWXNTAXLNYFJB-NKFFZRIASA-N

↓ lowered 2 findings in 2 endpoints · – no difference found 3 in 3

01 · the evidence, ordered

What the evidence says

Strong
0
Moderate
3
Limited
0
Very limited
2
Insufficient
0

How to read these marks

Fig. 2 Phylloquinone CHEBI:18067 5 endpoints 5 findings
×1.60
Labels
CompoundInspector

Phylloquinone

Most findings

  • All-site cancer incidence×1
  • Femoral neck bone mineral density×1
  • HOMA-IR×1
  • Lumbar spine bone mineral density×1
  • Serum undercarboxylated osteocalcin concentration×1

5 reference statements, not drawn · 36 compounds on the outer ring, not drawn

Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

  1. All-site cancer incidence
  2. Femoral neck bone mineral density
  3. Lumbar spine bone mineral density
  4. HOMA-IR
  5. Serum undercarboxylated osteocalcin concentration
fig. 3 · 5 endpoints · 5 findingsno endpoint contested

02 · findings

What phylloquinone moved, and by how much

  • HR hazard ratio. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
Direction
Strength, at least

5 shown

  1. All-site cancer incidenceMoved: lowersEffect, as reportedHR0.25[0.07 to 0.89]Evidence: ModeratePaper: PMID 189220412008
    Who
    Postmenopausal women with osteopenia, vitamin D replete, receiving calcium and vitamin D in both arms; follow-up up to 4 years
    Dose studied
    5 mg vitamin K1 daily

    Cancer incidence was lower in the vitamin K group than in the placebo group (three versus 12, p = 0.02; HR = 0.25, 95% CI 0.07 to 0.89).”

    Quoted verbatim from Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial.RCTPermalink
  2. Femoral neck bone mineral densityMoved: no difference foundEvidence: ModeratePaper: PMID 373386082023
    Who
    Post-menopausal women with osteoporosis and serum vitamin K1 of 0.4 µg/L or less, all on oral bisphosphonate with calcium and/or vitamin D; vitamin K1 arm against placebo, 18 months
    Dose studied
    1 mg/day vitamin K1

    Changes in BMD at the total hip, femoral neck and lumbar spine and BTMs; CTX and P1NP did not differ significantly following either K1 or MK-4 supplementation compared to placebo.”

    Quoted verbatim from The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial.RCTPermalink
  3. Lumbar spine bone mineral densityMoved: no difference foundEvidence: ModeratePaper: PMID 373386082023
    Who
    Post-menopausal women with osteoporosis and serum vitamin K1 of 0.4 µg/L or less, all on oral bisphosphonate with calcium and/or vitamin D; vitamin K1 arm against placebo, 18 months
    Dose studied
    1 mg/day vitamin K1

    Changes in BMD at the total hip, femoral neck and lumbar spine and BTMs; CTX and P1NP did not differ significantly following either K1 or MK-4 supplementation compared to placebo.”

    Quoted verbatim from The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial.RCTPermalink
  4. HOMA-IRMoved: no difference foundEvidence: Very limitedPaper: PMID 208810722010
    Who
    Community-dwelling postmenopausal women, 21 per arm; value at 12 months · n = 42
    Dose studied
    1 mg phylloquinone daily for 12 months

    Despite a decrease of ≈200% in ucOC concentrations, HOMA-IR was similar in the 2 groups at 6 and 12 mo (at 6 mo, HOMA-IR was 2.24 ± 0.54 and 1.52 ± 0.23 in the experimental and control groups, respectively; at 12 mo, HOMA-IR was 2.13 ± 0.38 and 1.47 ± 0.22 in the experimental and control groups, respectively; P = NS).”

    Quoted verbatim from Effect of phylloquinone supplementation on glucose homeostasis in humans.RCT · 12 monthsPermalink
  5. Serum undercarboxylated osteocalcin concentrationMoved: lowersEvidence: Very limitedPaper: PMID 172987082007
    Who
    Postmenopausal women in a 3 x 6-week randomised cross-over study; all periods included 10 microg vitamin D3/d; dose-dependent across placebo, 200 and 500 microg/d
    Dose studied
    0 (placebo), 200 and 500 microg phylloquinone/d, 6 weeks each

    With increasing phylloquinone intake, the concentration of serum gamma-carboxylated and under-gamma-carboxylated osteocalcin was significantly increased and decreased, respectively, in a dose-dependent manner (P < 0.001).”

    Quoted verbatim from Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women.crossover · 6 weeksPermalink

No dose is advised.

  • HR hazard ratio. Brackets: the interval as reported.
  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed

03 · identity

Structure

fig. 4Phylloquinone · 2D structure · ChEBI’s SMILES
Charge
0
SMILES
CC1=C(C/C=C(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=O)c2ccccc2C1=O

04 · figures · 1 plate

Plates

  • A dial of hairlines, each a peak of phylloquinone's measured mass spectrum, its angle the peak's mass-to-charge ratio and its length the peak's intensity.
    fig. 5Phylloquinone · MS2 [M+NH4]+ LC-ESI-QTOF positive · MassBank MSBNK-Antwerp_Univ-METOX_N108523_D7C8 (da Silva KM, CC BY)

05 · reach

What it touches on the way

5 entities · assembled from reference reactions

  1. CYP4F2Protein18 paths · 18 endpointsinferred
  2. VKORC1Protein17 paths · 17 endpointsinferred
  3. CYP4F11Protein13 paths · 13 endpointsinferred
  4. AIFM2Protein10 paths · 10 endpointsinferred
  5. VKORC1L1Protein5 paths · 5 endpointsinferred

06 · documented · reference

Interactions

Documented interactions
None reported

Pairs that share biology

What the reference databases state

Reference statements
501 ProteinAIFM2, VKORC1, VKORC1L1, CYP4F11, CYP4F2inferred, one hop from phylloquinone
Reactions · Rhea
6reactions
5Reference statements

What the reference databases state

Evidence key

Statements

5 statements

6Reactions

07 · on the label · 2,523 products

Labelled products

Source: NIH DSLD · Ingredient: phylloquinone · 2,523 products · Declared amount per serving (the first 1,000 shown): 3.3–80,000 µg

979 labels of the first 1,000 shown state an amount21 do not

  • 1st PhormM-Factor HeroVitamin K, as Phylloquinone80 µgper 3 capsulesDSLD:12881
  • 1st PhormPrenatal PlusPhytonadione60 µgper 3 vegan capsulesDSLD:242935
  • 21st CenturyDiabetic Support FormulaPhytonadione10 µgper 3 tabletsDSLD:11189
  • 21st CenturyMega Multi for MenVitamin K, as Phytonadione75 µgper 2 tabletsDSLD:258471
  • 21st CenturyMega Multi for WomenVitamin K, as Phytonadione75 µgper 2 tabletsDSLD:258472
  • 21st CenturyOne Daily ActivePhytonadione25 µgper 1 tabletDSLD:11548
  • 21st CenturyOne Daily Adults 50+Phytonadione20 µgper 1 tabletDSLD:11549
  • 21st CenturyOne Daily EnergyPhytonadione25 µgper 1 tabletDSLD:11552
  • 21st CenturyOne Daily EnergyVitamin K, as Phytonadione25 µgper 1 tabletDSLD:258482
  • 21st CenturyOne Daily MaximumPhytonadione25 µgper 1 tabletDSLD:11558
  • 21st CenturyOne Daily Men's HealthPhytonadione20 µgper 1 tabletDSLD:11559
  • 21st CenturyOne Daily Weight ControlPhytonadione80 µgper 1 tabletDSLD:11560
Show the remaining 2,511Show the first 12

Label record: NIH Office of Dietary Supplements · CC0

08 · the record

Sources

1,097

papers screened for phylloquinone

admitted
4
read and discarded
1,022
not read yet
71

The screening record, every paper and why

Sources cited

4 papers · 5 findings

Show every paper citedHide the papers cited